Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study

AIMS: To investigate how the cardiovascular (CV) risk benefits of dapagliflozin translate into healthcare costs compared with other non‐sodium–glucose cotransporter‐2 inhibitor glucose‐lowering drugs (oGLDs) in a real‐world population with type 2 diabetes (T2D) that is similar to the population of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Norhammar, Anna, Bodegard, Johan, Nyström, Thomas, Thuresson, Marcus, Rikner, Klas, Nathanson, David, Eriksson, Jan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899855/
https://www.ncbi.nlm.nih.gov/pubmed/31379124
http://dx.doi.org/10.1111/dom.13852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899855/
https://www.ncbi.nlm.nih.gov/pubmed/31379124
http://dx.doi.org/10.1111/dom.13852

Ejemplares similares